[DNA Damage Repair System and Antineoplastic Agents in Lung Cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The DNA damage repair (DDR) system is vital for maintaining genomic stability.
• Deficiencies in DDR or DNA lesions can drive cancer development and progression.
• DDR pathways present significant therapeutic targets for cancer treatment.

Purpose of the Study:

• To review the role of DNA damage and repair pathways in the antitumor activity of lung cancer agents.
• To summarize current applications and clinical investigations of these agents in lung cancer.
• To provide insights for developing precise and effective lung cancer treatment strategies based on DDR mechanisms.

Main Methods:

• Literature review of antineoplastic agents targeting DNA damage and repair in lung cancer.
• Analysis of chemotherapies, antibody-drug conjugates, targeted inhibitors, and immune-checkpoint inhibitors.
• Synthesis of information on DDR's role in antitumor responses and clinical outcomes.

Main Results:

• Many lung cancer antineoplastic agents are linked to DNA damage and repair pathways.
• Chemotherapies and antibody-drug conjugates induce DNA damage.
• Targeted drugs and immune-checkpoint inhibitors modulate DDR pathways for therapeutic effect.

Conclusions:

• Understanding DDR mechanisms is key to enhancing antitumor activity of current lung cancer therapies.
• Targeting DDR pathways offers promising avenues for precision medicine in lung cancer.
• Further exploration of DDR in lung cancer treatment can lead to more effective strategies.